SENP1-IN-4 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 21. SENP1-IN-4 is developed for tumor radiosensitivity enhancement [1].
In Vitro, SENP1-IN-4 improves the sensitivity of tumor cells to irradiation[1]. SENP1-IN-4 (0.7-20 μM; 72 hours) has cytotoxic for Hella cells with an IC50 of >20 μM[1].
References:
[1]. Li, Yiliang, et al. Preparation of ursolic acid derivatives useful as SENP1 inhibitors and tumor radiosensitizer. CN110627860A.
In Vitro, SENP1-IN-4 improves the sensitivity of tumor cells to irradiation[1]. SENP1-IN-4 (0.7-20 μM; 72 hours) has cytotoxic for Hella cells with an IC50 of >20 μM[1].
References:
[1]. Li, Yiliang, et al. Preparation of ursolic acid derivatives useful as SENP1 inhibitors and tumor radiosensitizer. CN110627860A.